Skip to main content
Premium Trial:

Request an Annual Quote

Sean Freeman

Molecular Assemblies has appointed Sean Freeman to its board of directors. Freeman currently serves as head of strategy and corporate development at NuVasive. He previously served as senior VP of business development for Cole-Parmer Instrument, and as head of corporate ventures and M&A at Life Technologies, which was later acquired by Thermo Fisher Scientific. He has also worked as an investment banker in Merrill Lynch's mergers & acquisitions group.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.